Highlight Therapeutics (Madrid, Spain) develops nanocomplexes of synthetic dsRNA that target PAMP receptors and TLRs to induce powerful immune responses. Bioncotech is clinically evaluating several immune-oncology combinations with its lead product. — Highlighttherapeutics.com
Location: Spain, Valencian Community, Valencia
Investors 3
Mentions in press and media 9
| Date | Title | Description | Source |
| 13.04.2022 | Highlight Therapeutics announces follow-up results from Phas... | BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma p... | globenewsw... |
| 15.03.2022 | Highlight Therapeutics to present at the American Associatio... | MADRID, Spain, March 15, 2022 (GLOBE NEWSWIRE) -- Highlight Therapeutics, ("Highlight"), a... | globenewsw... |
| 02.12.2021 | Highlight Therapeutics: BO-112 published in JITC | Intratumoral co-injection of BO-112 and a STING agonist synergize to achieve local and distant anti-... | globenewsw... |
| 13.11.2021 | Résultats positifs de la phase 2b pour le mélanome en 2e lig... | Highlight Therapeutics annonce les résultats préliminaires positifs de l'étude de phase 2b sur le BO... | globenewsw... |
| 12.11.2021 | Positive Phase 2b results in 2nd line melanoma | Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-P... | globenewsw... |
| 12.11.2021 | Positive Phase 2b results in 2nd line melanoma | BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma p... | globenewsw... |
| 02.03.2021 | Highlight & Pivotal start Phase IIa melanoma trial | Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to... | globenewsw... |
| 02.03.2021 | Highlight & Pivotal start Phase IIa melanoma trial | Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to... | marketscre... |
| 04.02.2021 | Highlight Therapeutics cierra una ronda de €22,6M liderada p... | 04/02/2021 HIGHLIGHT THERAPEUTICS CIERRA UNA RONDA DE €22,6 MILLONES LIDERADA POR COLUMBUS LIFE SCI... | webcapital... |